{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:59:42Z","timestamp":1789390782526,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1756-8722-7-25","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T02:38:22Z","timestamp":1395283102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice"],"prefix":"10.1186","volume":"7","author":[{"given":"Kaiyao","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting Tina","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhuang Joe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,19]]},"reference":[{"key":"390_CR1","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","volume":"112","author":"RL Levine","year":"2008","unstructured":"Levine RL, Gilliland DG: Myeloproliferative disorders. Blood. 2008, 112: 2190-2198. 10.1182\/blood-2008-03-077966.","journal-title":"Blood"},{"key":"390_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.leu.2404946","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A: The history of myeloproliferative disorders: before and after Dameshek. Leukemia. 2008, 22: 3-13. 10.1038\/sj.leu.2404946.","journal-title":"Leukemia"},{"key":"390_CR3","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med. 2006, 355: 2452-2466. 10.1056\/NEJMra063728.","journal-title":"N Engl J Med"},{"key":"390_CR4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.21543","volume":"85","author":"HM Kvasnicka","year":"2010","unstructured":"Kvasnicka HM, Thiele J: Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010, 85: 62-69.","journal-title":"Am J Hematol"},{"key":"390_CR5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007, 110: 1092-1097. 10.1182\/blood-2007-04-083501.","journal-title":"Blood"},{"key":"390_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W: Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011, 29: 573-582. 10.1200\/JCO.2010.29.8711.","journal-title":"J Clin Oncol"},{"key":"390_CR7","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","volume":"109","author":"G Finazzi","year":"2007","unstructured":"Finazzi G, Barbui T: How I treat patients with polycythemia vera. Blood. 2007, 109: 5104-5111. 10.1182\/blood-2006-12-038968.","journal-title":"Blood"},{"key":"390_CR8","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood-2010-08-270033","volume":"117","author":"PA Beer","year":"2011","unstructured":"Beer PA, Erber WN, Campbell PJ, Green AR: How I treat essential thrombocythemia. Blood. 2011, 117: 1472-1482. 10.1182\/blood-2010-08-270033.","journal-title":"Blood"},{"key":"390_CR9","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","volume":"117","author":"A Tefferi","year":"2011","unstructured":"Tefferi A: How I treat myelofibrosis. Blood. 2011, 117: 3494-3504. 10.1182\/blood-2010-11-315614.","journal-title":"Blood"},{"key":"390_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.disamonth.2012.01.002","volume":"58","author":"J Kim","year":"2012","unstructured":"Kim J, Haddad RY, Atallah E: Myeloproliferative neoplasms. Dis Mon. 2012, 58: 177-194. 10.1016\/j.disamonth.2012.01.002.","journal-title":"Dis Mon"},{"key":"390_CR11","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","volume":"100","author":"JL Spivak","year":"2002","unstructured":"Spivak JL: Polycythemia vera: myths, mechanisms, and management. Blood. 2002, 100: 4272-4290. 10.1182\/blood-2001-12-0349.","journal-title":"Blood"},{"key":"390_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.blre.2005.01.001","volume":"19","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Barbui T: Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005, 19: 243-252. 10.1016\/j.blre.2005.01.001.","journal-title":"Blood Rev"},{"key":"390_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365: 1054-1061. 10.1016\/S0140-6736(05)71142-9.","journal-title":"Lancet"},{"key":"390_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D\u2019Andrea A, Fr\u00f6hling S, D\u00f6hner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397. 10.1016\/j.ccr.2005.03.023.","journal-title":"Cancer Cell"},{"key":"390_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, Staerk J, Delhommeau F, Lacout C, Gar\u00e7on L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148. 10.1038\/nature03546.","journal-title":"Nature"},{"key":"390_CR16","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352: 1779-1790. 10.1056\/NEJMoa051113.","journal-title":"N Engl J Med"},{"key":"390_CR17","doi-asserted-by":"publisher","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005, 280: 22788-22792. 10.1074\/jbc.C500138200.","journal-title":"J Biol Chem"},{"key":"390_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1756-8722-4-4","volume":"4","author":"W Zhao","year":"2011","unstructured":"Zhao W, Gao R, Lee J, Xing S, Ho WT, Fu X, Li S, Zhao ZJ: Relevance of JAK2V617F positivity to hematological diseases\u2013survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011, 4: 4-10.1186\/1756-8722-4-4.","journal-title":"J Hematol Oncol"},{"key":"390_CR19","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","volume":"111","author":"S Xing","year":"2008","unstructured":"Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, Li Q, Fu X, Xu M, Zhao ZJ: Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008, 111: 5109-5117. 10.1182\/blood-2007-05-091579.","journal-title":"Blood"},{"key":"390_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0008-6363(98)00305-8","volume":"41","author":"A Nicoletti","year":"1999","unstructured":"Nicoletti A, Michel JB: Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 1999, 41: 532-543. 10.1016\/S0008-6363(98)00305-8.","journal-title":"Cardiovasc Res"},{"key":"390_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tice.2010.11.001","volume":"43","author":"A Castellar","year":"2011","unstructured":"Castellar A, Remedio RN, Barbosa RA, Gomes RJ, Caetano FH: Collagen and reticular fibers in left ventricular muscle in diabetic rats: Physical exercise prevents its changes?. Tissue Cell. 2011, 43: 24-28. 10.1016\/j.tice.2010.11.001.","journal-title":"Tissue Cell"},{"key":"390_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pharmthera.2013.01.001","volume":"138","author":"S Kennedy","year":"2013","unstructured":"Kennedy S, Wu J, Wadsworth RM, Lawrence CE, Maffia P: Mast cells and vascular diseases. Pharmacol Ther. 2013, 138: 53-65. 10.1016\/j.pharmthera.2013.01.001.","journal-title":"Pharmacol Ther"},{"key":"390_CR23","doi-asserted-by":"publisher","first-page":"e84340","DOI":"10.1371\/journal.pone.0084340","volume":"8","author":"X Jin","year":"2013","unstructured":"Jin X, Zhao W, Shi K, Ho WT, Zhao ZJ: Generation of a new congenic mouse strain with enhanced chymase expression in mast cells. PLoS One. 2013, 8: e84340-10.1371\/journal.pone.0084340.","journal-title":"PLoS One"},{"key":"390_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.7326\/0003-4819-149-1-200807010-00027","volume":"149","author":"S Gattenlohner","year":"2008","unstructured":"Gattenlohner S, Ertl G, Einsele H, Kircher S, Muller-Hermelink HK, Marx A: Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease. Ann Intern Med. 2008, 149: 69-71. 10.7326\/0003-4819-149-1-200807010-00027.","journal-title":"Ann Intern Med"},{"key":"390_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1634\/stemcells.2004-0293","volume":"23","author":"K Foshay","year":"2005","unstructured":"Foshay K, Rodriguez G, Hoel B, Narayan J, Gallicano GI: JAK2\/STAT3 directs cardiomyogenesis within murine embryonic stem cells in vitro. Stem Cells. 2005, 23: 530-543. 10.1634\/stemcells.2004-0293.","journal-title":"Stem Cells"},{"key":"390_CR26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V91.2.419","volume":"91","author":"S Ogilvy","year":"1998","unstructured":"Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM: Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998, 91: 419-430.","journal-title":"Blood"},{"key":"390_CR27","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/0002-9343(81)90827-5","volume":"70","author":"RL Letcher","year":"1981","unstructured":"Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH: Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med. 1981, 70: 1195-1202. 10.1016\/0002-9343(81)90827-5.","journal-title":"Am J Med"},{"key":"390_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/eurheartj\/14.5.597","volume":"14","author":"FG Fowkes","year":"1993","unstructured":"Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT: The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74\u00a0years. Eur Heart J. 1993, 14: 597-601. 10.1093\/eurheartj\/14.5.597.","journal-title":"Eur Heart J"},{"key":"390_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0895-7061(99)00011-4","volume":"12","author":"Y Cinar","year":"1999","unstructured":"Cinar Y, Demir G, Pa\u00e7 M, Cinar AB: Effect of hematocrit on blood pressure via hyperviscosity. Am J Hypertens. 1999, 12: 739-743. 10.1016\/S0895-7061(99)00011-4.","journal-title":"Am J Hypertens"},{"key":"390_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2362.2005.01437.x","volume":"35","author":"G Ciuffetti","year":"2005","unstructured":"Ciuffetti G, Schillaci G, Lombardini R, Pirro M, Vaudo G, Mannarino E: Prognostic impact of low-shear whole blood viscosity in hypertensive men. Eur J Clin Invest. 2005, 35: 93-98. 10.1111\/j.1365-2362.2005.01437.x.","journal-title":"Eur J Clin Invest"},{"key":"390_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010, 363: 1117-1127. 10.1056\/NEJMoa1002028.","journal-title":"N Engl J Med"},{"key":"390_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1756-8722-6-79","volume":"6","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Cortes J: Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013, 6: 79-10.1186\/1756-8722-6-79.","journal-title":"J Hematol Oncol"},{"key":"390_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1756-8722-5-43","volume":"5","author":"J Randhawa","year":"2012","unstructured":"Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S: Splenomegaly in myelofibrosis\u2014new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 2012, 5: 43-10.1186\/1756-8722-5-43.","journal-title":"J Hematol Oncol"},{"key":"390_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O\u2019Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013, 6: 81-10.1186\/1756-8722-6-81.","journal-title":"J Hematol Oncol"},{"key":"390_CR35","first-page":"47","volume":"29","author":"J Hoff","year":"2000","unstructured":"Hoff J: Methods of blood collection in the mouse. Lab Anim. 2000, 29: 47-53.","journal-title":"Lab Anim"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-7-25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T04:29:51Z","timestamp":1716611391000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-7-25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,19]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-7-25","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,19]]},"assertion":[{"value":"10 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"25"}}